GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Liabilities-to-Assets

Kyverna Therapeutics (Kyverna Therapeutics) Liabilities-to-Assets : 0.07 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Kyverna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $28.99 Mil. Kyverna Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $389.98 Mil. Therefore, Kyverna Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.07.


Kyverna Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Kyverna Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Liabilities-to-Assets Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Liabilities-to-Assets
1.54 2.11 2.75

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial 2.11 - 2.21 2.75 0.07

Competitive Comparison of Kyverna Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Kyverna Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyverna Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Liabilities-to-Assets falls into.



Kyverna Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Kyverna Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=206.592/75.195
=2.75

Kyverna Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=28.993/389.984
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyverna Therapeutics  (NAS:KYTX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Kyverna Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines